MDGL - Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development | Benzinga
RBC Capital Markets downgraded 89Bio Inc (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for liver and cardio-metabolic diseases.
The analyst maintains a positive outlook on the long-term prospects of the FGF21 class drugs, considering it as a fundamental approach to addressing NASH (Non-Alcoholic Steatohepatitis) and other metabolic-related ailments.
Additionally, RBC Capital is optimistic about ETNB’s pegozafermin (BIO89-100), which it sees as a strong contender in this space, particularly given recent favorable trial designs facilitated by the FDA.
However, the analyst anticipates ...